Guolan Wu

Guolan Wu

Auto-generated profile, based on publicly available information

Guolan Wu

Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Journal of Chromatography B
Verified
Journal Article
Closed access
YZYunliang Zheng
Yunliang Zheng
XHXingjiang Hu
Xingjiang Hu
YZYou Zhai
You Zhai
JLJian Liu
Jian Liu
GWGuolan Wu
Guolan Wu
JSJianzhong ShenTu
Jianzhong ShenTu

21 April 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
GWGuolan Wu
Guolan Wu
WTWenling Tang
Wenling Tang
DLDuo Lv
Duo Lv
LWLihua Wu
Lihua Wu
HZHuili Zhou
Huili Zhou
JSJianzhong Shentu
Jianzhong Shentu
The effects of multiple-dose administration of tenofovir disoproxil fumarate (TDF) on the pharmacokinetics of morinidazole (MOR) were compared in healthy subjects. MOR exposure was similar, with an area under the curve from 0 h to infinity (AUC 0-∞ ) treatment ratio for MOR+TDF/MOR of 1.01 (90% confidence interval, 0.97 to 1.06). No relevant differences were observed regarding plasma exposure of metabolites. Renal clearances of MOR and its metabolites were not affected by TDF.

1 January 2024 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
GWGuolan Wu
Guolan Wu
FZFeng Zhou
Feng Zhou
HWHaiping Wang
Haiping Wang
KLKan Liu
Kan Liu
DYDexin Yu
Dexin Yu
JSJianzhong Shentu
Jianzhong Shentu
Background: A newly generic microspheres, sustained-release formulation of triptorelin acetate 3.75 mg has been developed. Objectives: To evaluate the efficacy, pharmacokinetics, and safety of triptorelin 1-month formulation in Chinese patients with prostate cancer. Design: An open-label, multicenter clinical trial with one arm testing a 1-month sustained-release triptorelin formulation in prostate cancer patients. Methods: Patients with prostate cancer received three consecutive 28-day injections of triptorelin acetate. The primary endpoint was the proportion of successful patients over the total number of evaluable patients. Treatment success was defined as testosterone suppression below the clinical castration level (i.e., <0.5 ng/mL) at day 28 and maintenance of clinical castration until study completion (day 84). The frequency of patients with testosterone concentrations <0.2 ng/mL was also studied. Results: The study included 125 patients. All 125 patients received at least one dose of the study drug and 122 completed the study. The successful patient proportion among the evaluable patients was 97.6% (122/125; 95% CI, 92.7–99.2). 95.1% (116/122) achieved testosterone concentrations <0.2 ng/mL. The pharmacokinetic profile of triptorelin during the first 3 months of treatment, evaluated in a subset of the study population ( n = 11), showed sustained release of triptorelin from the formulation. Values for AUC0−τ calculated from day 0 to 28, and day 56 to 84 were 134.42 (28.76), and 154.72 (21.86) h*ng/mL, respectively. The most common treatment-related adverse events were increased alanine aminotransferase (18.4%), increased aspartate aminotransferase (16.0%), and hot flashes (9.6%). Prolonged QT interval on electrocardiogram, erectile dysfunction, and decreased libido each occurred in ⩽4% of the patients. The frequently reported local adverse reaction was pain at the injection site, experienced by 2.4% (3/125) of the patients. Conclusion: 3.75-mg Triptorelin acetate microspheres for injection were effective in achieving and maintaining testosterone suppression and were well tolerated in patients with prostate cancer. Trial registration: chictr.org.cn (ChiCTR2000033188).

22 August 2025 in Drugs in R&D
Verified
Journal Article
Open access
PDF file
YYYinglin Yang
Yinglin Yang
JKJiejing Kai
Jiejing Kai
DLDuo Lv
Duo Lv
HZHuili Zhou
Huili Zhou
YYYan Yu
Yan Yu
GWGuolan Wu
Guolan Wu
Background and Objectives Flunarizine, a selective calcium channel blocker with vasodilatory and neuroprotective effects, is a mainstay for migraine prophylaxis and vertigo management. This study aimed to compare the bioequivalence, pharmacokinetics, and safety of test and reference flunarizine hydrochloride capsules after a single oral dose under fasting/fed conditions. Methods A randomized, open-label, two-formulation, single-dose, two-period crossover bioequivalence study was conducted under fasting and fed conditions. Eligible healthy Chinese subjects received a single 5-mg dose of the test or reference flunarizine hydrochloride capsules, followed by a 21-day washout interval between periods. Blood samples were collected up to 36 h post-dose. Pharmacokinetic parameters were calculated using noncompartmental methods, and bioequivalence was assessed via geometric mean ratios of the test/reference for primary pharmacokinetic parameters, along with 90% confidence intervals. Tolerability was evaluated during the entire study period. Results Twenty-four volunteers completed the fasting study, while 42 volunteers completed the fed study. The test formulation demonstrated bioequivalence to the marketed formulation, with 90% confidence intervals for geometric mean ratios of peak plasma concentration (fasting: 97.38–106.57%; fed: 92.71–109.58%), area under the curve from time 0 to 36 h (fasting: 98.20–108.09%; fed: 93.79–100.81%), and AUC from time 0 to infinity (fasting: 97.88–107.30%; fed: 93.63–100.53%), all within equivalence limits of 80.00–125.00%. High-fat meals delayed the time to maximum concentration by 2.5 h and increased exposure by 20%. Both the test and reference formulations were well tolerated, and no serious adverse events related to the study drug were reported during the study. Conclusions This study confirmed that test and reference flunarizine hydrochloride capsules were bioequivalent under fasting and fed conditions. Clinical Trial Registration ChiCTR1900026713.